Lowering Drug Prices by Once Again Putting Americans First

Executive Order Number: 14273
President: Donald Trump
Signed: April 15, 2025
Published: April 18, 2025
Source: Federal Register
Original Document: https://www.govinfo.gov/content/pkg/FR-2025-04-18/pdf/2025-06837.pdf

AI-Generated Summary

Executive Order Summary

Purpose

The purpose of this executive order is to restore and enhance previous initiatives aimed at reducing prescription drug prices for American patients. It criticizes the reversal of earlier policies by the Biden Administration and aims to improve upon the Inflation Reduction Act's Medicare Prescription Drug Negotiation Program.

Key Actions or Directives

Improving the Medicare Drug Price Negotiation Program: The Secretary of Health and Human Services (HHS) is tasked with proposing guidance to enhance transparency, prioritize high-cost drugs, and minimize negative impacts on innovation.
Stabilizing Medicare Part D Premiums: Recommendations to stabilize and reduce Medicare Part D premiums are to be provided within 180 days.
Aligning Small Molecule and Biological Drugs: The HHS Secretary is to work with Congress to align the treatment of small molecule drugs with biological products under the Medicare Drug Price Negotiation Program.
Developing a New Payment Model: A new payment model for high-cost drugs not covered by the Medicare Drug Price Negotiation Program is to be developed and tested within one year.
Surveying Hospital Acquisition Costs: A survey to determine hospital acquisition costs for outpatient drugs is to be conducted, followed by proposals for adjustments to Medicare payments.
Enhancing Medicaid Drug Payment Oversight: Recommendations to ensure accurate Medicaid drug rebates and promote innovation in payment methodologies are to be provided within 180 days.
Ensuring Access to Affordable Medications: Future grants under the Public Health Service Act will be conditioned on health centers making insulin and injectable epinephrine available at discounted prices to low-income individuals.
Evaluating Middlemen's Role: Recommendations to improve the pharmaceutical value chain's competitiveness and transparency are to be provided within 90 days.
Accelerating Competition for Drugs: A report with recommendations to accelerate approval of generics and biosimilars and improve the reclassification process for over-the-counter drugs is to be issued within 180 days.
Increasing Drug Importation: Steps to streamline the Importation Program to facilitate state approval for drug importation are to be taken within 90 days.
Reducing Costly Care for Seniors: An evaluation to ensure Medicare payments do not encourage a shift to more expensive hospital outpatient departments is to be conducted within 180 days.
Improving Transparency in Pharmacy Benefit Managers: Proposed regulations to enhance transparency into pharmacy benefit managers' compensation are to be issued within 180 days.
Combating Anti-Competitive Behavior: Joint public listening sessions and a report with recommendations to reduce anti-competitive behavior by drug manufacturers are to be conducted within 180 days.

Significant Changes to Policy or Law

The order seeks to modify the Medicare Drug Price Negotiation Program to address the "pill penalty" by aligning the treatment of small molecule drugs with biological products.
It introduces new payment models and surveys to align Medicare payments with actual acquisition costs.
It conditions future grants on health centers providing affordable access to insulin and injectable epinephrine for low-income individuals.
It proposes regulatory changes to enhance transparency and competition within the pharmaceutical industry.

Potential Impacts

Government Agencies: HHS and its various departments, including the Office of Management and Budget, will be directly involved in implementing the order's directives, potentially requiring additional resources and coordination.
Citizens: American patients, particularly seniors and low-income individuals, may benefit from lower prescription drug prices and increased access to affordable medications.
International Relations: The order's focus on increasing drug importation could affect relations with countries from which drugs are imported, depending on the implementation of the Importation Program.

Main Stakeholders Affected

Patients and Consumers: Especially seniors and low-income individuals who rely on Medicare and Medicaid for prescription drug coverage.
Pharmaceutical Industry: Manufacturers, particularly those producing small molecule drugs, and pharmacy benefit managers may face increased regulation and scrutiny.
Healthcare Providers: Hospitals, physician offices, and health centers will need to adapt to new payment models and grant conditions.
Government Agencies: HHS, the Department of Justice, the Department of Commerce, the Federal Trade Commission, and the Office of Management and Budget will be involved in implementing and overseeing the order's directives.

Notable Legal, Constitutional, or Political Implications

Legal Implications: The order does not create enforceable rights or benefits, maintaining the discretion of executive agencies in implementation. It also requires actions to be consistent with existing laws, which may limit the scope of changes.
Constitutional Implications: The order is issued under the President's authority as granted by the Constitution and laws of the United States, aligning with traditional executive powers in health policy.
Political Implications: The order reflects a continuation of previous administration policies and a critique of the current administration's approach, potentially fueling political debates over healthcare and drug pricing. It may also influence legislative discussions on healthcare reform, especially concerning Medicare and Medicaid.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.